Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents

AIDS

Volumn 25, Issue 12, 2011, Pages 1489-1496

  Kiser, Jennifer J ^a   Rutstein, Richard M ^b   Samson, Pearl ^c   Graham, Bobbie ^d   Aldrovandi, Grace ^e   Mofenson, Lynne M ^f   Smith, Elizabeth ^g   Schnittman, Steven ^h   Fenton, Terry ^c   Brundage, Richard C ⁱ   Fletcher, Courtney V ^j  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f NICHD   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ UNIVERSITY OF MINNESOTA   (United States)

^j NEBRASKA MEDICAL CENTER   (United States)

more..

Author keywords

atazanavir; children; HIV; pediatrics; pharmacokinetics; protease inhibitor

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR;

ADOLESCENT; ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CHILD; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SOUTH AFRICA; UNITED STATES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; SOUTH AFRICA; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 79960565299     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328348fc41     Document Type: Article

References (14)

1. World Health Organization. Global Summary of the HIV/AIDS epidemic. Geneva: WHO Press; 2009. http://www.who.int/hiv/data/2009-global-summary.png. [Accessed 21 February 2011]
2. WHO. Countdown to 2015 decade report (2000-2010): taking stock of maternal, Newborn, and Child Survival. Geneva: WHO Press; 2010. http://whqlibdoc.who.int/publications/2010/9789241599573-eng.pdf. [Accessed 8 June 2010]
3. Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P. International perspectives, progress, and future challenges of paediatric HIV infection. Lancet 2007; 370:68-80. (Pubitemid 47018314)
4. Hazra R, Siberry GK, Mofenson LM. Growing up with HIV: children, adolescents, and young adults with perinatally acquired HIV infection. Annu Rev Med 2010; 61:169-185.
5. Johnson M, Grinsztejn B, Rodriguez C, Coco J, DeJesus E, Lazzarin A, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-694. (Pubitemid 40593073)
6. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53:323-332.
7. Murphy RL, Sanne I, Cahn P, Phanuphak P, Percival L, Kelleher T, Giordano M. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviralnaive subjects: 48-week results. AIDS 2003; 17:2603-2614. (Pubitemid 38402338)
8. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36:1011-1019. (Pubitemid 38989366)
9. Division of AIDS Regulatory Support Center. Table for grading severity of pediatric adverse experiences greater than 3 months of age. 1994. http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table-for-Grading- Severity-of-Pediatric-AEs-Over3MonthsAge-v03.pdf. [Accessed 8 June 2010]
10. BristolMyersSquibb. Reyataz prescribing information. 2010. http://packageinserts.bms.com/pi/pi-reyataz.pdf.
11. Acosta E, Limoli K, Trinh L, Parkin N, King J, Weidler J, et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data [abstract 633]. In: 18th Conference on Retroviruses and Opportunistic Infections; 27 February to 2 March 2011; Boston, Massachusetts, USA.
12. Agarwala S, Eley T, Filoramo D, Wang Y, Mathew M, Frederick D, et al. Steady-state pharmacokinetics and inhibitory quotient of atazanavir with and without ritonavir in treatment naive HIV-infected patients [abstract 85]. In: 7th International Workshop on Clinical Pharmacology of HIV Therapy; 20-22 April 2006; Lisbon, Portugal.
13. Torres J, Perez-Perez G, Goodman KJ, Atherton JC, Gold BD, Harris PR, et al. A comprehensive review of the natural history of Helicobacter pylori infection in children. Arch Med Res 2000; 31:431-469. (Pubitemid 32117619)
14. Taburet AM, Piketty C, Chazallon C, Vincent I, Gerard L, Calvez V, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096. (Pubitemid 38691603)